Fluorodeoxyglucose F18
Established medicineAlso known as (18F)-FDG, 18-F FDG, 18F-FDG, 18F-Fluorodeoxyglucose+7 more
(18F)-FDG, 18-F FDG, 18F-FDG, 18F-Fluorodeoxyglucose, Fludeoxyglucose (18F), Fluorine (18F) fludeoxyglucose, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, FLUDEOXYGLUCOSE F 18, FLUDEOXYGLUCOSE F-18, Fludeoxyglucose F18, Fludeoxyglucose, F-18.
Recent clinical, regulatory, research and industry developments relating to this drug.
Supplemental approval: FLUDEOXYGLUCOSE F 18 (ANDA079086)
2023 ESC Guidelines for the management of endocarditis.
Label change: FLUDEOXYGLUCOSE F 18 (ANDA079086)
Label change: FLUDEOXYGLUCOSE F 18 (ANDA079086)
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- Journal of nuclear medicine : official publication, Society of Nuclear Medicine4
- European heart journal2
- Annals of neurology1
- Brain : a journal of neurology1
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America1
- Cold Spring Harbor perspectives in medicine1
- Delbeke D2
- Erba PA2
- Lowe VJ2
- Mestres CA2
- Minoshima S2
- Miro JM2
- Ossenkoppele R2
- Pizzi MN2
- Helen Wills Neuroscience Institute2
- Johns Hopkins University School of Medicine2
- Mayo Clinic2
- Aix Marseille University1
- Alzheimer Center1
- Amsterdam University Medical Center1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 10 of the same disease areas as Fluorodeoxyglucose F18 in the shared literature.
Studied across 8 of the same disease areas as Fluorodeoxyglucose F18 in the shared literature.
Studied across 4 of the same disease areas as Fluorodeoxyglucose F18 in the shared literature.
Studied across the same disease area as Fluorodeoxyglucose F18 in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.